Journal of Pain and Symptom Management
Volume 35, Issue 5 , Pages 535-543 , May 2008

Potential Drug Interactions in Cancer Patients Receiving Supportive Care Exclusively

  • Rachel P. Riechelmann, MD

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Camilla Zimmermann, MD, MPH

      Affiliations

    • Department of Psychosocial Oncology and Palliative Care, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Sheray N. Chin, MD

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Lisa Wang, BSc

      Affiliations

    • Department of Biostatistics, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Aoife O'Carroll, MD

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Sanaz Zarinehbaf, MD

      Affiliations

    • Department of Psychosocial Oncology and Palliative Care, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    • ,
  • Monika K. Krzyzanowska, MD, MPH

      Affiliations

    • Department of Medical Oncology and Hematology, Princess Margaret Hospital, University of Toronto, Toronto, Ontario, Canada
    • Corresponding Author InformationAddress correspondence to: Monika K. Krzyzanowska, MD, MPH, Department of Medical Oncology and Hematology, Princess Margaret Hospital, 610 University Avenue, Suite 5-227, Toronto, ON M5G 2M9, Canada.

,Accepted 21 June 2007.

References 

  1. Egger SS, Drewe J, Schlienger RG. Potential drug-drug interactions in the medication of medical patients at hospital discharge. Eur J Clin Pharmacol. 2003;58:773–778
  2. Geppert U, Beindl W, Hawranek T, et al. [Drug interactions in clinical practice. A pilot project for quality assurance in prescribing], Hautarzt. 2003;54:53–57
  3. Glintborg B, Andersen SE, Dalhoff K. Drug-drug interactions among recently hospitalised patients—frequent but mostly clinically insignificant. Eur J Clin Pharmacol. 2005;61:675–681
  4. Karas S. The potential for drug interactions. Ann Emerg Med. 1981;10:627–630
  5. Herr RD, Caravati EM, Tyler LS, et al. Prospective evaluation of adverse drug interactions in the emergency department. Ann Emerg Med. 1992;21:1331–1336
  6. Goldberg RM, Mabee J, Chan L, et al. Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. Am J Emerg Med. 1996;14:447–450
  7. Davidson KW, Kahn A, Price RD. Reduction of adverse drug reactions by computerized drug interaction screening. J Fam Pract. 1987;25:371–375
  8. Stiztel CCR. Modern pharmacology with clinical application, Philadelphia, PA: Lippincott-Williams, 1997.
  9. Haddad A, Davis M, Lagman R. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer. 2007;15:251–257
  10. Buajordet I, Ebbesen J, Erikssen J, et al. Fatal adverse drug events: the paradox of drug treatment. J Intern Med. 2001;250:327–341
  11. Riechelmann RP, Moreira F, Smaletz O, et al. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56:286–290
  12. Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99:592–600
  13. Jenkins CA, Schulz M, Hanson J, et al. Demographic, symptom, and medication profiles of cancer patients seen by a palliative care consult team in a tertiary referral hospital. J Pain Symptom Manage. 2000;19:174–184
  14. Nauck F, Ostgathe C, Klaschik E, et al. Drugs in palliative care: results from a representative survey in Germany. Palliat Med. 2004;18:100–107
  15. Riechelmann RP, Krzyzanowska MK, O'Carroll A, et al. Symptom and medication profiles among cancer patients attending a palliative care clinic. Support Care Cancer. 2007;15(12):1407–1412
  16. Twycross RG, Bergl S, John S, et al. Monitoring drug use in palliative care. Palliat Med. 1994;8:137–143
  17. Koh NY, Koo WH. Polypharmacy in palliative care: can it be reduced?. Singapore Med J. 2002;43:279–283
  18. Mercadante S, Fulfaro F, Casuccio A. Pattern of drug use by advanced cancer patients followed at home. J Palliat Care. 2001;17:37–40
  19. Zimmermann C, Seccareccia D, Clarke A, et al. Bringing palliative care to a Canadian cancer center: the palliative care program at Princess Margaret Hospital. Support Care Cancer. 2006;14:982–987
  20. Facts and comparisons 4.0. St. Louis: Wolters Kluwer Health; 2006;Available at http://online.factsandcomparisons.comAccessed January 23, 2007
  21. Barrons R. Evaluation of personal digital assistant software for drug interactions. Am J Health Syst Pharm. 2004;61:380–385
  22. Lackner TE. Interaction of dexamethasone with phenytoin. Pharmacotherapy. 1991;11:344–347
  23. Drummond SH, Peterson GM, Galloway JG, et al. National survey of drug use in palliative care. Palliat Med. 1996;10:119–124
  24. Curtis EB, Walsh TD. Prescribing practices of a palliative care service. J Pain Symptom Manage. 1993;8:312–316
  25. Williamson EM. Interactions between herbal and conventional medicines. Expert Opin Drug Saf. 2005;4:355–378
  26. Yoon SL, Schaffer SD. Herbal, prescribed, and over-the-counter drug use in older women: prevalence of drug interactions. Geriatr Nurs. 2006;27:118–129
  27. Mahe I, Bertrand N, Drouet L, et al. Paracetamol: a haemorrhagic risk factor in patients on warfarin. Br J Clin Pharmacol. 2005;59:371–374
  28. Costedoat-Chalumeau N, Amoura Z, Aymard G, et al. Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone. Ann Intern Med. 2000;132:631–635
  29. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005;352:1112–1120
  30. Murphy MJ, Dominiczak MH. Efficacy of statin therapy: possible effect of phenytoin. Postgrad Med J. 1999;75:359–360
  31. Brackett CC, Bloch JD. Phenytoin as a possible cause of acetaminophen hepatotoxicity: case report and review of the literature. Pharmacotherapy. 2000;20:229–233
  32. Tenni P, Lalich DL, Byrne MJ. Life threatening interaction between tamoxifen and warfarin. BMJ. 1989;298:93
  33. Gerson LB, Triadafilopoulos G. Proton pump inhibitors and their drug interactions: an evidence-based approach. Eur J Gastroenterol Hepatol. 2001;13:611–616
  34. Edelman J, Potter JM, Hackett LP. The effect of intra-articular steroids on plasma salicylate concentrations. Br J Clin Pharmacol. 1986;21:301–307
  35. White WB. Hypotension with postural syncope secondary to the combination of chlorpromazine and captopril. Arch Intern Med. 1986;146:1833–1834
  36. de Jong JC, van den Berg PB, Tobi H, et al. Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects. Br J Clin Pharmacol. 2003;55:591–595
  37. Ahmed A. Interaction between aspirin and angiotensin-converting enzyme inhibitors: should they be used together in older adults with heart failure?. J Am Geriatr Soc. 2002;50:1293–1296

PII: S0885-3924(07)00747-6

doi: 10.1016/j.jpainsymman.2007.06.009

Journal of Pain and Symptom Management
Volume 35, Issue 5 , Pages 535-543 , May 2008

Article Tools